- IMIDAZOQUINOLINE-TYPE COMPOUNDS AND USES THEREOF
-
Provided in the present disclosure are imidazoquinoline-type compounds, methods for their preparation, pharmaceutical compositions thereof and their use, wherein the imidazoquinoline-type compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.
- -
-
Paragraph 0013; 00106; 00116
(2021/10/11)
-
- Novel carboxylated pyrroline-2-one derivatives bearing a phenylhydrazine moiety: Design, synthesis, antifungal evaluation and 3D-QSAR analysis
-
Aiming to discover novel high-efficient antifungal leads that possess an innovative action mechanism, twenty-three carboxylated pyrroline-2-one derivatives, bearing a phenylhydrazine moiety, were rationally designed and firstly prepared in this letter. The in vitro bioassays showed that most of the compounds possessed excellent antifungal effects with the EC50 values of less than 1 μg/mL against the phytopathogenic fungi Fusarium graminearum (Fg), Botrytis cinerea (Bc), Rhizoctonia solani (Rs) and Colletotrichum capsici (Cc). The further bioassays showed that the compound 6u showed the comparable in vivo control effect with carbendazim against fusarium head blight and rice sheath blight. The 3D-QSAR model revealed the pivotal effects of a bulky electron-donating group at the 1-position of pyrrole ring, a bulky electron-withdrawing group at the 4-position of phenyl ring and a small alkyl at the carbonate group on the anti-Rs activities of target compounds. The abnormal mycelial morphology and delayed spore germination were observed in the treatments of compound 6u. Given the excellent and broad-spectrum antifungal effects the target compounds have, we unfeignedly anticipated that the above finding could motivate the discovery of high-efficient antifungal leads, which might possess an innovative action mechanism against phytopathogenic fungi.
- Chen, Min,Zhang, Lizhi,Lu, Aimin,Wang, Xiaobin,Si, Weijie,Yan, Jinghua,Yang, Chunlong
-
-
- LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES
-
Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.
- -
-
Paragraph 0032; 00186-00187; 00197
(2020/10/19)
-
- Cell-Penetrating Dynamic-Covalent Benzopolysulfane Networks
-
Cyclic oligochalcogenides (COCs) are emerging as promising systems to penetrate cells. Clearly better than and different to the reported diselenolanes and epidithiodiketopiperazines, we introduce the benzopolysulfanes (BPS), which show efficient delivery, insensitivity to inhibitors of endocytosis, and compatibility with substrates as large as proteins. This high activity coincides with high reactivity, selectively toward thiols, exceeding exchange rates of disulfides under tension. The result is a dynamic-covalent network of extreme sulfur species, including cyclic oligomers, from dimers to heptamers, with up to nineteen sulfurs in the ring. Selection from this unfolding adaptive network then yields the reactivities and selectivities needed to access new uptake pathways. Contrary to other COCs, BPS show high retention on thiol affinity columns. The identification of new modes of cell penetration is important because they promise new solutions to challenges in delivery and beyond.
- Cheng, Yangyang,Zong, Lili,López-Andarias, Javier,Bartolami, Eline,Okamoto, Yasunori,Ward, Thomas R.,Sakai, Naomi,Matile, Stefan
-
supporting information
p. 9522 - 9526
(2019/06/24)
-
- Efficient synthesis of some new antiproliferative N-fused indoles and isoquinolines via 1,3-dipolar cycloaddition reaction in an ionic liquid
-
Syntheses of some new pyrrolo-fused pyrrolo[1,2-a] indole derivatives have been achieved by combining N-allyl-indole-2-carbaldehyde with a variety of N-alkyl-glycine esters as well as tetrahydroisoquinolines in an ionic liquid, triethylammonium acetate (TEAA), a recyclable reaction medium, via intramolecular [3+2] cycloaddition reaction. This new method is highly efficient, and the ionic liquid employed is recyclable. The stereochemistry of all the compounds was confirmed by 2D NMR NOESY and in some cases single crystal X-ray diffraction data. The in vitro screening of all new candidates against various bacterial strains and representative human solid tumor cell lines, A549 (lung), HeLa (cervix), SW1573 (lung), T-47D (breast) and WiDr (colon), revealed that many of them have good antibacterial, antifungal and antitubercular and antiproliferative activities.
- Sutariya, Tushar R.,Labana, Balvantsingh M.,Parmar, Narsidas J.,Kant, Rajni,Gupta, Vivek K.,Plata, Gabriela B.,Padrón, José M.
-
supporting information
p. 2657 - 2668
(2015/04/14)
-
- A convenient 1,3-dipolar cycloaddition-reduction synthetic sequence from 2-allyloxy-5-nitro-salicylaldehyde to aminobenzopyran-annulated heterocycles
-
A microwave-assisted, one-pot synthesis of some nitro benzopyran-annulated pyrroles as well as pyrrolo-fused isoquinolines via a 1,3-dipolar cycloaddition, which involves the in situ generation of azomethine ylide formed by reacting secondary amines with 2-allyloxy-5-nitro-salicylaldehyde, has been achieved in a solvent-free environment. Compared to methods of conventional and thermal heating, the present microwave-assisted method is rapid and highly efficient. In addition, amino analogous heterocycles were successfully accessed after treating the reaction mass further with iron in acidic medium, which also highlights a one-pot procedure for a new 1,3-dipolar cycloaddition-reduction synthetic sequence. All amino-products are new bioprofiles and anticipated to be effective drug-like candidates. All compounds were characterised based on their elemental analysis, mass, IR, and 1H and 13C NMR spectroscopic data. The stereochemistry of the product was confirmed by 2D NMR COSY and NOESY experiments, which, on the basis of single crystal X-ray diffraction data analysis, was further confirmed and supported.
- Parmar, Narsidas J.,Pansuriya, Bhavesh R.,Labana, Balvantsingh M.,Kant, Rajni,Gupta, Vivek K.
-
p. 17527 - 17539
(2013/09/24)
-
- An improved microwave assisted one-pot synthesis, and biological investigations of some novel aryldiazenyl chromeno fused pyrrolidines
-
An improved microwave assisted one-pot method for the synthesis of twelve new aryldiazenylchromeno [4,3-b] pyrrolidines via intramolecular azomethine ylide cycloaddition route is described. The method is efficient and advantageous over conventional and solvent-free thermal methods. The stereochemistry of the compounds was confirmed on the basis of various NMR experiments, and finally by single crystal X-ray diffraction data. N-Methyl or ethyl pyrrolidine based heterocycles gave good biological activities.
- Parmar, Narsidas J.,Pansuriya, Bhavesh R.,Barad, Hitesh A.,Kant, Rajni,Gupta, Vivek K.
-
supporting information; experimental part
p. 4075 - 4079
(2012/07/03)
-
- Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline
-
Chronic immune activation is a hallmark of progressive HIV infection. Recent reports point to the engagement of toll-like receptor 7 (TLR7) and -9 by viral RNA as contributing to the activation of innate immune responses, which drive viral replication leading to immune exhaustion. The only known class of TLR7 antagonists is single-stranded phosphorothioate oligonucleotides, which has been demonstrated to inhibit immune activation in human and Rhesus macaque in vitro models. The availability of a selective and potent small-molecule TLR7 antagonist should allow the evaluation of potential benefits of suppression of TLR7-mediated immune activation in HIV/AIDS. Gardiquimod is a known N1-substituted 1H-imidazoquinoline TLR7 agonist, the synthesis of which has not been published. We show that the 3H regioisomer is completely inactive as a TLR7 agonist and is weakly antagonistic. A des-amino precursor of the 3H regioisomer is more potent as a TLR7 antagonist, with an IC50 value of 7.5 μM. This class of compound may serve as a starting point for the development of small-molecule inhibitors of TLR7.
- Shukla, Nikunj M.,Kimbrell, Matthew R.,Malladi, Subbalakshmi S.,David, Sunil A.
-
supporting information; experimental part
p. 2211 - 2214
(2009/12/07)
-